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ABSTRACT
Introduction: Chagas disease (CD) is a worldwide problem, with over 8 million people infected in
both rural and urban areas. CD was first described over a century ago, but only two drugs are
currently available for CD treatment, benznidazole (BZN) and nifurtimox (NF). Treating CD infected
patients, especially children and women of reproductive age, is vital in order to prevent long term
sequelae, such as heart and gastrointestinal dysfunction, but this aim is still far from being
accomplished. Currently, the strongest data to support benefit-risk considerations come from
trials in children. Finally, treatment response biomarkers need further development as serology is
being questioned as the best method to assess treatment response.

Areas covered: This article is a narrative review on the pharmacology of drugs for CD, particularly
BZN and NF. Data on drug biopharmaceutical characteristics, safety and efficacy of both drugs are
summarized from a clinical perspective. Current data on alternative compounds under evaluation
for CD treatment, and new possible treatment response biomarkers are also discussed.

Conclusion: Early diagnosis and treatment of CD, especially in pediatric patients, is vital for an
effective and safe use of the available drugs (i.e. BZN and NF). New biomarkers for CD are urgently
needed for the diagnosis and evaluation of treatment efficacy, and to guide efforts from academia
and pharmaceutical companies to accelerate the process of new drugs development.
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INTRODUCTION
Chagas disease (CD) is a zoonosis caused by infection with Trypanosoma cruzi, a protozoan
parasite. Humans can acquire this infection by contact with insect vectors (hematophagous
triatomine or Reduviidae bugs), by ingestion of contaminated food1, congenital transmission,
blood transfusions or organ or tissue transplants from infected donors. In the past, CD was
believed to exclusively affect rural populations in Latin America, but movement of people from
rural to urban areas (as well as expanding screening strategies to urban dwellers), has revealed the
infection as a worldwide problem2,3. Congenital transmission in particular has become an
important route of infection and the main reason for acute CD in non-endemic countries, such as
North America and Europe.
The World Health Organization (WHO) estimates that over 8 million people worldwide are
infected with T cruzi, and that an excess of 10,000 deaths occur every year due to CD 2. Underdiagnosis of CD cases is suspected to be as high as 90%, and even higher in cases of congenital CD
which is alarming considering that estimated T. cruzi prevalence among pregnant women ranges
from 2% to 40% depending on geographical area 4,5.
CD has a clinical course characterized by an acute phase, commonly asymptomatic, that
resolves spontaneously in most cases but which can sometimes (i.e. less than 5% of cases) be
severe, leading to serious sequelae and even death. Following the acute phase, a chronic stage
ensues, with patients usually remaining asymptomatic for many decades. However, approximately
30% of infected patients eventually develop progressive and irreversible target organ damage,
mainly in the heart and/or esophagus and colon. The ‘silent’ asymptomatic phase between acute
and chronic phases is referred to as ‘indeterminate stage’ by some authors.6,7
The decision to implement CD treatment was historically based on age, due to limited
evidence of efficacy, and an increasing frequency and severity of side effects in relation to patient
age. 8 Currently there is agreement in international clinical guidelines that anti-parasitic treatment
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is effective and therefore should be offered at least to 1) patients with acute CD, 2) all children
with congenital or acquired acute CD 3) immunosuppressed hosts with acute or reactivation of
chronic disease 4) women of childbearing age in order to prevent congenital transmissions 9–12.
Treatment effectiveness in chronic CD continues to be highly debated 13–15; for adults over
50 years old, trypanocidal therapy is still considered optional due to an unclear risk-benefit
balance. On the one hand there is a general agreement that parasitic persistence increases the risk
for development or progression of cardiac lesions in chronically infected patients and therefore
parasite eradication may be necessary in the early stages of the disease 16,17. On the other hand,
advanced CD seems to involve irreversible cardiac damage, and therefore parasiticidal treatment
of affected older patients may be futile13. However, the evidence for either position is still
limited18.
Unfortunately, anti-parasitic therapy has not been widely implemented, even for those
age groups that can clearly benefit from it (e.g. pediatric patients, early chronic infections, etc.) in
spite of existing national and international guidelines that support treatment. This failure to treat
may possibly be explained by many obstacles, including health care providers’ low awareness of
CD and its treatment options, overblown concerns about side effects, low access to healthcare for
many patients with CD, lack of an optimal straightforward test of CD cure, widespread drug
shortages and irregular supplies, and regulatory barriers19. Even though WHO 2020 Goals for CD
included access to treatment and/or care of all infected/ill patients, and The London Declaration
on Neglected Tropical Diseases 20 announced plans for the elimination or control of Chagas disease
by 2020, current estimates indicate that less than 1% of CD infected patients are treated and those
lofty aims are far away from becoming a reality.21 Sub-optimal CD treatment implementation
continues in many countries in spite the fact that failing to treat a CD patient could be considered
medical negligence in many jurisdictions22.
In South America, CD causes the loss of over 750,000 working days because of premature
deaths and $1.2 billion in productivity loss every year 23. The calculated annual global burden of
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disease is over $600 million dollars per year in health-care costs and 10% of this burden affects
non-endemic countries24. According to a study conducted in Mexico that evaluated the impact and
economic outcomes (costs, cost-effectiveness, cost-benefit) of identifying and treating different
percentages of CD patients in the acute and indeterminate phases, identifying and treating CD
cases earlier was always economically dominant compared to no treatment21. Authorities in
charge of health policies should acknowledge that this would result not only in reduced
transmission rates and better health outcomes but also in huge cost-savings, besides being a
medical duty, and human rights issue.
Despite the fact that CD was first described over a century ago25, only two drugs are
currently available for treatment, benznidazole (BZN) and nifurtimox (NF), which were developed
over 40 years ago. Both drugs require prolonged treatments (30 to 60 days) and are associated
with adverse events that increase in severity and prevalence with age. Prompt diagnosis and
treatment, especially in pediatric patients, are vital for an effective use of these medications.

PHARMACOLOGICAL TREATMENT OF CD
Both NF and BZN are nitroheteroerocyclic drugs developed over four decades ago by Bayer
and Roche, respectively. Their mechanism of action is believed to rely on intracellular activation,
that generates intermediates affecting the parasite’s vital biological functions 26,27. Both drugs are
highly liposoluble, with very low water solubility. The parasite`s mechanisms against these drugs
relies on detoxifying molecules such as trypanothione 28 a vital part of the free radical scavenging
cycle that is recycled by the enzyme trypanothione disulfide reductase.
Treatment with BZN and NF is contraindicated during pregnancy in most guidelines, due to
limited evidence on safety, yet there is evidence of low concentration of BZN or NF in breastmilk
with no risk to infants during lactation 29–31.
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These drugs are usually not recommended in patients with renal or hepatic impairment,
mostly on the basis of lack of safety data. However, given that these drugs are almost completely
metabolized, renal elimination only plays a marginal role in their clearance and use in kidney
failure would be possible with appropriate monitoring for adverse events. Similarly, in cases
requiring emergency treatment (e.g. CD meningoencephalitis), hepatic impairment should not be
an obstacle for treatment assuming that strict monitoring can be implemented 32.
Although BZN is more commonly used than NF, both drugs seem to have similar efficacy
and safety profiles. Reported treatment responses in the chronic indeterminate phase in children
(mostly based on measuring serologic titers) are near 90% after NF treatment 33 and 94% for BNZ
34,35

. In adults NF has treatment response rate of 7-8% 36,37 and BZN between 2 and 40% 13,38, with

more studies carried for BZN than NF in this area (see table 1). There are no current data formally
comparing both drugs, but some clinical studies are currently ongoing attempting to address this
issue, such as TESEO (NCT03981523)39.
Unfortunately, given the natural history of CD and heterogeneity of response follow-up
techniques, it is logistically challenging to treat this disease during the earlier asymptomatic
chronic phase and follow that patient cohort to determine clinical outcomes, which can take
decades to appear, with sufficient statistical power to differentiate potential effects in treated
versus control patients. About 30 years ago two controlled placebo clinical trials assessed the
efficacy of treatment in CD chronic phase in pediatric patients with good results35,40, and other
studies followed those, leaving no doubt that the earlier children are treated, the better the
response achieved8,40,41. Women in fertile age should also be treated to prevent congenital CD
transmission9,40–42.
Unlike treatment for children or women of reproductive age, controversies regarding
treatment of adult patients still abound; in 2016 the first prospective multi-centric and
randomized CD cohort study in older adults with advanced CD, the `Benznidazole Evaluation for
Interrupting Trypanosomiasis’ (BENEFIT), was published, describing the outcomes of

2854
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patients with established Chagas heart disease that received BZN or placebo and were followed
for 5.4 years13. This study concluded that no significant morbidity or mortality reduction was
achieved with anti-parasitic treatment in patients with advanced cardiac stage. On the other side,
the evidence from cohort and historical controlled trials has supported treating most chronic
patients at early stages, with the available drugs16,43–47.
Monitoring treatment is recommended for either drug, with complete blood counts,
hepatic, and renal function testing. Frequency varies through different guidelines between every
two and five weeks, always with a pre-treatment laboratory evaluation to compare later
findings34,48.

BENZNIDAZOLE
Brief Recent History

Benznidazole (N- phenylmethyl-2-nitro-1H-imidazole-1-acetamide; CAS Number 22994-850) is the most commonly used drug for treatment of CD. It was developed by Roche (Ro 07-1051)49
and there have been three producers of BZN so far: Roche, Lafepe (public pharmaceutical
company of Brazil), and Chemo (formerly Elea, an Argentine pharmaceutical company). Roche
manufactured and distributed the drug (as Radanil© or Rochagan©) from 1967 until the early
2000s, when production was discontinued due to economic reasons49. Later, encouraged by
pressure from scientific and medical organizations, Roche eventually transferred BZN production
technology and remaining stocks to Lafepe, which committed to re-establish supply. Lafepe
developed a pediatric formulation for children weighing < 20 kg (12.5 mg tablet) that was tested in
clinical pediatric study in Argentina (sponsored by Drugs for Neglected Diseases initiative)8 and this
formulation was registered in Brazil in 2011 and was included on the WHO’s Essential Medicines
List for children in 2013.
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BNZ was the first drug approved by the United States Food and Drug Administration (FDA)
in 2017 for children ages two to twelve years with CD50,51 and in April 2018, a pediatric formulation
of BZN was approved in Argentina to treat children under the age of 2 years. BZN is also prescribed
off-label for adolescents, adults, and children under 2 in countries where the drug has not been
registered specifically for these age groups.
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BNZ Pharmacology

Benznidazole is an oral, broad spectrum nitroimidazole antimicrobial that has activity
against bacteria and several parasites. It has demonstrated efficacy against in vitro T. cruzi strains
in several in vivo animal models

52–56

. According to the Biopharmaceutical Classification System

(BCS)57,58 BNZ belongs to Class IV drugs (reduced solubility and permeability); it is a liposoluble
drug with very low solubility in water, and a weak base at physiological pH range. BNZ solubility in
distilled water or simulated gastric and enteric fluids is reported between 0.2 mg/ml and 0.4
mg/ml. According to this, BZN is classified as a low-permeability drug with a log P of 1.6458.
BZN is considered a prodrug, requiring activation by parasite nitroreductase enzymes that
reduce BZN, initiating a cascade of reactions leading to the formation of highly reactive drug
metabolites27. The main parasite enzyme involved in BZN activation is believed to be a type 1
nitroreductase. The resulting BZN metabolites, such as dialdehyde glyoxal, bind to parasite
macromolecules disrupting T. cruzi metabolism and other vital functions, and leading to parasite
cell death27. However, using a metabolomics approach to asses BZN mechanism of action,
Trochine et al. proposed that the covalent binding of BZN with low molecular weight thiols as well
as with protein thiols is a primary cause of the drug's toxicity against T. cruzi, instead of glyoxal
generation as formerly stated59. This suggests that BZN acts in a complex manner and there are
still some remaining uncertainties about its mechanisms of action: metabolomic studies are a
promising frontier in this research area.
T cruzi resistance to BZN is not well described in literature. Some in-vitro studies have
reported that some parasite strains have a ‘natural’ in-vitro resistance to BZN associated with
overexpression of ABCG transporter60, but this evidence has been questioned, as in-vitro results
do not correlate with therapeutic outcomes in humans61. Other studies with in vitro data suggest
that susceptibility of different T.cruzi strains to BZN fluctuates, but the 50% inhibitory
concentration (IC50) values remain ≤19.5 μg/mL (75 μM) and can vary 10-fold within the same
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assay. Activity against different forms of the parasite (epimastigotes, trypomastigotes, or
amastigotes) also appears to vary within a relatively small range62,63, and it should be considered
that many studies are performed on the epimastigote stage, which is easier to culture but not the
human stage of the parasite. Additionally, time-kill studies indicate that BZN trypanocidal effect is
both time and concentration dependent 62–64. Using multiple T.cruzi strains and a high-throughput
screening platform, a rapid trypanocidal effect was demonstrated with 100% parasite clearance
against multiple divergent T. cruzi genotypes, a rate superior to that for ergosterol biosynthesis
inhibitors63.
After oral administration, BZN is quickly absorbed from the human intestine (Ka = 1.14/h),
with a plasmatic peak within 2–4 hours after drug intake8,65. The impact of food on absorption has
not been systematically investigated. Some evidence points to first step elimination by hepatic
biotransformation and entero-hepatic recirculation, possibly with some degree of enteric
metabolism as well, but little research has been conducted in this area. Absolute bioavailability in
humans has never been formally estimated due to the absence of an intravenous formulation apt
for human use, though a mean relative oral bioavailability of 91.7% in three healthy adults when
comparing liquid to solid oral formulations was reported66. Steady-state plasma concentrations are
reached within 3 days of initiation of a twice-daily dosing regimen8,66. BZN distributes widely into
tissues, including the central nervous system (CNS)67,68, with higher volume of distribution in
children compared to adults8. The drug reaches CNS concentrations close to 70% of those
observed in plasma, which has allowed successful treatment of Chagas CNS infections (e.g.
meningoencephalitis) in immunosuppressed patients69–72. Plasma protein binding of BZN is
approximately 50% and is thus not expected to lead to significant interactions with other drugs 54.
Clearance of BZN is mainly by biotransformation (>80%) 68,73, believed to take place mostly
in the liver, probably by members of the cytochrome P450 (CYP) family and/or tissue nitroreductases. However, few studies to date have explored the details of the metabolic pathways
responsible for BZN elimination. Approximately 6–20% of the drug can be found unchanged in
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urine, with differences depending on age of the patient (e.g., children seem to eliminate more
unchanged drug in urine compared to adults); and the rest of the drug has been observed as
reduced and conjugated.74
Mean BZN half-life is 13 hours in adults66 and significantly shorter in children (3 to 6 hours
for 2 to 7 year-old patients and 9 to 10 hours in children 7 to 12 years) as observed in two
prospective clinical trials8. This difference in clearance and half-life between different age groups
implies average steady-state concentrations of BZN lower in children than in adults. Interestingly,
this difference does not seem to affect the efficacy of BNZ since in a prospective clinical trial, all
treated children showed good response to treatment despite lower plasma concentrations of the
drug8. When comparing the data obtained in this study with previously reported adult results66, a
progressive decrease in the clearance rate of BZN with increasing age was observed (i.e. the older
the patient, the slower the drug was eliminated). The specific mechanisms for drug elimination in
children and adults remain undiscovered. Research in the area is actively testing different
hypotheses such as slower drug metabolism in adults and impaired drug absorption in younger
children. BNZ pharmacokinetics and treatment response in teenagers and young adults have never
been studied, so the assumption that it would be in between children and adults is so far
unsupported by actual evidence.
The most commonly used BNZ dosing regimen, reported in the majority of the evidence
published to date (see table 1) uses doses ranging from 5 to 8 mg/kg/day orally, in two daily doses
for 30 to 60 days. BZN can also be administered in three daily doses, with a clear tendency in
international guides for recommending 5 rather than 8 mg/kg/day and twice daily rather than
thrice.48
Duration of treatment in children and adults is currently under review and some expert
guides are already recommending shorter treatments8,75, supported by the fact that treatment in
children is proven to be effective despite differences in PK with adults leading to lower
concentrations and shorter half-lives, without detectable drop in effectiveness and with less
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adverse reactions8,75. A few trials enrolling children who received 30 days of treatment have
showed good results42,76, and recent evidence points towards possible efficacy of lower BNZ doses
or less frequent dosing for adults and teenagers too65,77,78. Lower treatment duration has also
proven to be effective in adults in preliminary results of an unpublished clinical trial
(NCT03378661) that showed 89.3% of therapeutic response (measured as a negative PCR) after a 4
week treatment compared to 82.8% after 8 week-treatment. There are currently other ongoing
trials addressing BZN daily doses and duration as well such as BETTY trial79 and MULTIBENZ
(NCT03191162), that may change treatment regimen in the next few years, assuming that
sustained long term responses are demonstrated.
The most commonly observed adverse drug reactions (ADRs) associated with BZN use
include rash and pruritus, headache, myalgia, and gastrointestinal discomfort. Skin reactions
characteristically appear between 7 to 12 days after the start of treatment. Drug-associated
hepatitis, leucopenia, peripheral neuropathy, and severe drug hypersensitivity (Stevens-Johnson
syndrome and other reactions with systemic symptoms) have also been reported but less
frequently. The median proportion of severe side effects is 2.7%.45 Trough BZN serum
concentrations did not appear to be related to the appearance of serious ADRs in a small study in
adults80, but evidence for a concentration-adverse event relationship has been observed in
pediatric studies8,34. A recent prospective study in 99 participants reported some previously
unreported ADRs; ten subjects presented psychiatric symptoms (anxiety, panic attacks, emotional
lability and persecutory delusions), four patients reported sexual alterations (erectile dysfunction
or delay in menstrual cycle with no alternative explanations) and one patient had a bronchospasm.
The results of this study were in other aspects similar to previously published literature about BZN
adverse reactions.81 The safety profile of BZN in children is well described in the literature; data
are consistent and do not suggest any signals of clinical concern8,34.
The incidence of ADRs between children and adults has not been compared directly (i.e. in
a study enrolling both age groups), but ADRs seem rare and almost universally mild in younger
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children, and appear to increase gradually after 7 years of age in both frequency and severity. It is
very infrequent to observe ADRs in newborns and children under 1 year old, and rates of
treatment discontinuation due to ADRs are significantly low in children 34,47,76,82–85 while these
ranges between 11 and 45% in adult studies16,45,82,86.
The underlying biological mechanisms for the observed ADRs have not been studied in
depth, but the immune system seems to play an important role, particularly in the case of
cutaneous rashes and hypersensitivity reactions. This assumption is based on the timing for the
moderate cutaneous reactions (7–12 days after onset of treatment) that mimics the time course of
similar reactions associated to other unrelated medications known to cause rash (e.g. lamotrigine),
and the observation of rare severe adverse reactions such as Stevens-Johnson syndrome and drug
reactions with eosinophilia and systemic symptoms83,84. A common immunological trigger for
these reactions and possibly a pharmacogenetic predisposition could explain these similarities, but
studies of potential pharmacogenomic markers are missing. Some authors had formerly proposed
to associate BZN with thioctic acid in order to prevent ADRs, based on this compound to increase
hepatic elimination of BZN, but this has proven not to be effective when evaluated in-vivo.87
BZN has never been formally studied during pregnancy, but it is not recommended for
pregnant women due to the lack of safety data; there is insufficient information about
reproductive safety of this drug, other than the fact that there have been no reports of
malformations or any other pregnancy complications. However, it should be considered that it is
likely that an unknown number of women were exposed to BZN in the first trimester by accident
and the lack of reports on safety data might be a good sign so far. Also, there are some reports of
treatment during late-stage pregnancy in emergency situations that did not result in any
complications for the baby and may have saved the mother’s life69. The main recommendation
therefore remains to avoid BZN during the first trimester of pregnancy and throughout pregnancy
whenever possible until further information becomes available, though in case of an emergency or
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a life-threatening situation caused by CD, we recommend not delaying treatment because of an
unproven teratogenic risk69.
BNZ has been classically contraindicated during lactation, but recent prospective studies
and pharmacokinetic evaluations suggest that the risk of exposure to BZN from breastmilk for a
breastfed baby is negligible, and lactation should not be considered a contraindication for CD
treatment in those circumstances when treatment cannot be postponed. 29
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NIFURTIMOX

Brief Recent History

NF was manufactured in the 1970s by Bayer -as Lampit®- but its development started
earlier, in the 1960s as Bayer-2502. Similar to what happened with BZN, Bayer discontinued
production in the 1990s due to low demand and almost null profitability, but reconsidered and
restarted production later. Since then, country-level access to the drug has depended on individual
states’ agreements and negotiations with WHO and Bayer, and local bureaucratic and political
decisions. Availability currently seems erratic in many South American countries, but it is expected
to improve in the near future, after a clinical trial performed in children -CHICO study
(NCT02625974) - that supported FDA approval of NF formulations for CD in the pediatric
population.

Nifurtimox Clinical Pharmacology

Many aspects of NF clinical pharmacology are similar to those of BZN. There is also
considerable lack of knowledge on many aspects of its PK, effectiveness, and metabolism.
However, NF is currently undergoing extensive redevelopment, with some clinical trials already
completed and others in process (NCT04274101) (see table 1).
NF mechanism of action is believed to be the generation of nitro-anion radicals, after
activation by parasite nitroreductases in the presence of oxygen. This leads to production of free
radicals that damage vital T. cruzi cell components, block DNA synthesis and accelerate DNA and
RNA degradation88,89.
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Similarly to BZN, NF is hydrophobic, highly liposoluble and distributes widely to tissues,
including the central nervous system90, a useful property for the treatment of T. cruzi CNS
infections. It has a rapid absorption from gut (Ka 0.77/h), but undergoes extensive first-pass
elimination (much higher than BZN), leading to only a small fraction of orally administered NF
reaching systemic circulation91,92. NF is administered orally and reaches peak plasma
concentrations after 2 to 4 hours32,90,93 with a relatively short half-life (approximately 3 hours in
adults, and similar in children based on very limited data) 94,95. Liver elimination accounts for
virtually all NF clearance (i.e., unchanged NF elimination in urine is less than 1% of the
administered dose).96
According to a recent trial that reported biopharmaceutical characteristics after oral
administration of 30 mg and 120 mg tablets 96, total systemic exposure to NF was approximately
71% greater after food than in a fasted state. Mean (%CV) NF AUC estimates ranged between
1676-2670 µg∙h/L (19–32%) and Cmax estimates ranged between 425-568 µg/L (26–50%)
following administration of single dose 120 mg NF with food in adult CD patients. The median time
to reach maximum concentration (Tmax) of NF under fed conditions was 4 hours (range: 2 to 8
hours). Interestingly, in this study Cmax increased 68%, AUC increased 71%, and Tmax increased
by 1 hour after a high-fat meal compared to fasted conditions.96
Animal liver experiments of NF metabolism have suggested a number of metabolites97, but
this aspect has only been studied in a limited number of humans, with preliminary confirmation of
the metabolites observed in animal experiments and further observation of a range of minor
metabolites98. Data from animal studies also suggests that CYP enzymes are responsible for NF
metabolism, but no human data is publicly available identifying specific CYP isoforms, or
associated enzymes, responsible for biotransformation98,99. NF plasma protein binding is
approximately 50% and not expected to play a significant role in drug-drug interactions100. This
drug is a substrate for the ABCG2 transporter, commonly known as Breast Cancer Resistance
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Protein (BCRP), which has been shown to influence NF transport across the blood-brain barrier, as
well as its excretion into breastmilk 30,31,101.
NF apparent volume of distribution is high (V/F = 760 L), suggesting both an extensive
distribution into tissues and also a significant pre-systemic elimination (i.e., a limited
bioavailability), such as that observed in animal studies 91.
Neither NF optimal dose nor the optimal treatment duration for CD is well defined.
Initially, treatments tended to be long (90–120 days)102 but were subsequently reduced to mimic
BZN treatment spans (approximately 60 days)103,104. The recent trial CHICO study (NCT02625974)
studied alternative dosing (30 versus 60 days) observing similar serological and parasitological
treatment responses for children under 2 years; but in order to apply these conclusions to all
pediatric patients, long term follow-up would be crucial. Commonly used dose ranges from 8 to 15
mg/kg/day divided in three daily administrations, but optimal daily dose frequency has never been
duly studied either, and was defined only on the basis of NF half-life.
The most commonly observed ADRs are anorexia and weight loss, irritability, sleepiness,
and other nervous system signs and symptoms83,103,105. NF use is also associated with rash,
pruritus, and drug-associated hepatitis but less frequently than BZN. Depression, peripheral
neuropathy, and psychiatric symptoms have also been reported, less commonly. Similar to BZN,
NF-associated ADRs seem much more common and severe in adults and are usually mild in
children, including neonates96,106,107. Notably, there is some evidence that suggests that patients
who develop a severe drug reaction to BZN may still be treated safely with NF 108.
Similar to BZN, NF is considered contraindicated during pregnancy and lactation: virtually
no data is available on the safety of this drug during the first trimester of pregnancy, and therefore
it is still advisable to avoid its use at this stage. About lactation, recently published and ongoing
studies on NF transfer into breastmilk strongly suggest that the drug is safe during breastfeeding,
and treatment of a lactating mother should not be discouraged if needed30,31.
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ASSESSMENT OF TREATMENT EFFICACY: EXISTING BIOMARKERS OF TREATMENT
RESPONSE AND NEW ADVANCES

The appropriate markers of CD cure (i.e. a patient being free from CD and not at risk of
developing target organ involvement such as cardiomyopathy, cardiac failure, mega-esophagus or
mega-colon, etc.) have been subject to intense debate for decades, in part due to prolonged
persistence of T.cruzi specific antibodies, lack of sensitivity of parasitological tests, and need for
long-term follow-up (generally years or decades) to observe negative seroconversion of
conventional serological tests, as well as a general lack of understanding of the parasite biology in
the human and the kinetics of drug response. Serology (and, in particular, negative
seroconversion) has been heralded for many years as the gold standard for treatment response,
largely guided by the successful results observed after treating acute infections or early chronic
infections in children8,109 (see table 1). However, treatment of older patients, or even children
over 7 years of age, does not lead to negative seroconversion for decades (if ever) 8,40,42,109, even if
a drop in antibody titers is observed early after pharmacological treatment. This fact is easy to
understand, if one considers that persistent immune system stimulation (e.g. as would be the case
in chronic CD due to persistent antigen shedding by deep-tissue T cruzi nests) is bound to generate
immune responses that would last for a long time even after complete parasite clearance by NF or
BZN.
Negative seroconversion continues to be the (somehow arbitrarily) chosen method to
ascertain a treatment response, both in general practice and research. Reported serologic
response rates are as high as 96% for congenitally infected infants

8,109–111

, 76% for acute

infections112, 63% 40,113 to 90% 113 for chronically infected children, and 37% for chronically infected
adults 114. These rates have marked variability among different published studies due to different

This article is protected by copyright. All rights reserved

serologic techniques employed, with sometimes poorly evaluated, different sensitivities and
specificities, used to determine treatment response as the primary outcome of clinical trials115,116.
It would be reasonable to consider that more sensitive serological techniques would
under-estimate time and rates of cure (i.e. would yield positive antibody results with lower titers),
with no correlation with clinical outcomes such as organ impact, but this still requires more
research to confirm. In order to study the correlation between serologic response and organ
damage, a recent study of a pediatric cohort performed a median after treatment follow-up of 10
years of treated children with electrocardiograms (ECG), 24 hours ECG (Holter) and Speckletracking strain echocardiography and observed no CD untoward impact on heart function in this
population years after treatment, supporting the low correlation between serological tests and
clinical response117. Also, T. cruzi detection tests currently in use in some countries for long term
follow up of patients such as polymerase chain reaction against T.cruzi-DNA (PCR) or different
serology techniques, were initially developed for diagnostic purposes. Furthermore, many of the
methods used have been repeatedly changed across the years, and comparison of results from
recent clinical studies to older studies involves a degree of uncertainty even if comparing tests that
are nominally the same (e.g. RT-PCR done in recent years would have used primers and protocols
very different to those used 10 years ago)

41,46

. In this context, new markers of cure are needed.

Alternative early markers of cure have been suggested, such as decrease of total anti-T.cruzi
antibody titers (i.e. instead of negative seroconversion) or use of non-conventional serological
techniques

118,119

such as specific lytic anti-α-Gal antibodies known as anti-F2/3 antibodies120.

Other CD biomarkers suggested by scientific literature so far have been reviewed by different
authors too, but the general impression is that they all still require more research, and validation.
Table 2 summarizes the biomarkers studied.46,121,122
PCR has been proposed as a sensitive and specific method to detect T.cruzi parasitemia in
newborns41,123,124 and has also shown good results for the assessment of treatment failure, as a
persistently positive result after treatment clearly is evidence of failure to eliminate the
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parasite125. However, while PCR may be more sensitive than current methods in some cases, the
lack of standardization of the method across centers is a still unresolved issue. Furthermore, actual
rate of false positives is still under debate, and may vary among testing laboratories (and different
techniques used). Other issues such as cost and instrument availability and technical skills,
conspire to limit the use of this method at the moment, but considering its good results so far and
its feasibility of being easily applied in clinical settings, the investment in improving PCR
methodologies is worthwhile. The CD community must focus on suitable strategies for parasite
DNA extraction in lower sample volumes, the equivalence between blood and tissue parasitemia;
the reduction of false negatives, as well as the validation and standardization of PCR assays; and
the equivalence of PCR readouts with negative seroconversion.109,126–128
Considering all available evidence, we could conclude that despite the need of trials in this
area, a negative PCR -associated to a persistent decrease of T.cruzi antibodies titers- should be the
chosen criteria used to assess treatment response and to follow-up after treatment in our time.
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PHARMACOLOGICAL TREATMENT: NEW TREATMENT STRATEGIES AND
ALTERNATIVE DRUGS
As mentioned before, there are few recent advances in BZN and NF pharmacology, which
is disappointing considering their longevity. Some improvements in drug formulation have been
proposed (e.g. application of nanotechnologies such as nanocrystals, polymeric nanoparticles, and
lipid nanostructures) as an attractive approach to improve solubility and dissolution of BNZ and
NFX, hopefully leading to dose reductions and, perhaps, novel treatment schemes, but virtually no
clinical research has been undertaken with this proposed formulations 129,130.
New potentially effective drugs have been proposed on the basis multiple targets in the
parasite cell. Ergosterol biosynthesis enzymes in particular have been well studied, and CYP51
(sterol 14-Demethylase) was proposed as an interesting target, both due to its importance in
parasite survival, and the availability of multiple medications already in the market (i.e. azole
antifungal drugs) that could be easily repositioned for clinical trials in CD

104,131–134

. This

repositioning approach is advantageous in view of the cost and time-consuming process required
compared to the development of new medicines, especially in neglected diseases, since
repositioned drugs already have their toxicological and pharmacokinetic profile assessed when
used on their previous therapeutic target 135. Unfortunately, only allopurinol and a few azoles have
been studied in clinical trials, observational studies, and case reports - there is an ongoing
randomized double-blind, placebo controlled trial being carried (NCT03193749) comparing
Amiodarone hydrochloride with placebo but there are no preliminary results disclosed so far.
Despite allopurinol has shown to be useful in combination with NF or Benznidazole in small trials,
evidence is still insufficient136–138. From azoles, posaconazole was compared in high and low doses
versus placebo and research results concluded it has an acceptable antitrypanosomal activity, but
also a significant increase in treatment failure compared with BZN group 139. Another randomized

This article is protected by copyright. All rights reserved

placebo-controlled trial in adults tested E1224 (a ravuconazole pro-drug in different dosing
regimens) and BZN versus placebo, and found that E1224 + BZN group displayed a transient,
suppressive effect on parasite clearance, whereas BZN showed early and sustained efficacy until
12 months of follow-up. This transitory effect was shown only in high dose sub-group while
parasite levels in the low-dose and short-dose E1224 groups gradually returned to placebo levels
140

. In summary, from azole`s research, some former promising repositionable drugs such as

monotherapy with ketoconazole, ravuconazole or posaconazole has not proven to be efficacious
for the treatment of chronic T. cruzi infection 139–141 and the combination of posaconazole and BZN
did not provide any further efficacy or safety advantages over BZN monotherapy 142,143.
Similarly, pre-clinical studies have identified interesting targets for drug action including
cruzipain (parasite lysosomal cysteine), B citocrome, trypanothione reductase system, cyclophilins,
N-myristoylome, carbonic anhydrases and NMDA glutamate receptor. 143,144 However, none of
these targets have drugs in clinical trials yet, and the ever-mounting costs of drug development
and human clinical trials make it difficult to believe that many new molecules for CD would be
coming into the market in the foreseeable future.
Fexinidazole is a drug previously repositioned for Trypanosoma brucei gambiense infection
(African trypanosomiasis) after demonstrating effectiveness in a randomized controlled trial

145

.

Also, fexinidazole`s safety and pharmacokinetics had been properly studied in humans, proving
that oral administration is safe and well tolerated

132,133,146

. Considering this drug is effective in

clearing T.cruzi as well in pre-clinical studies, an ongoing randomized, double-blind, placebo
controlled trial is being carried out in Argentina, Bolivia and Spain to assess its efficacy in CD
(NCT02498782).
Interestingly, some natural compounds and dietary supplements such as microalgae
extracts147, wasp venom148, coumarins149, South American Vernonieae150,

curcumin151

and

Resveratrol152 have been also studied for anti-tripanosomal activity, but more research is required
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to draw conclusions, and there is still close to no human clinical data. The use of natural
compounds to treat known diseases might lead to effective benefit-cost resources, considering
that many of these compounds are not subject to patent restrictions and may be widely available.
However, formal clinical testing should be performed before any of these compounds is used in
patients.104
In spite of a relative abundance of preclinical molecular candidates and potential
repositionable drugs, there are currently no new classes of drugs in the clinical development
pipeline for CD and BZN and NF remain the only two available drugs for treatment with relatively
solid clinical data to support their use.

Conclusion
CD is a highly neglected tropical disease that has become an increasing worldwide
problem in last decades. There is an alarming number of undiagnosed and untreated patients, and
an urgent need for researchers and providers to change this fact. The choice for treatment
remains between two drugs, created a century ago. The strongest data to support benefit-risk
considerations come from trials in children (see Table 1).
Scientific and economic effort should be urgently aimed to supply early diagnose and
treatment in this population, in addition to more research in this area. New biomarkers for CD are
strongly needed for the diagnosis and detection of treatment efficacy and efforts from academia
and pharmaceutical companies to accelerate the process of new drugs development are
necessary. Also, an extra effort to standardize a predictive Chagas disease in vivo model should be
done and validated in order to improve its predictability and to ease its comparison and
reproducibility.
Early diagnosis and treatment of Chagas diseases, especially in pediatric patients, are vital
for an effective and safe use of the available drugs (BZN and NF) medications.
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Table 1: Summary of relevant trials of Benznidazole and/or Nifurtimox in children

Author/
Reference

Moscatelli et
al 2019 109

Robello et al.
2019
153

Albareda et
al. 2018
47

Patient
Population

IP* of CD <20 years
of age
Argentina

IP* of CD 5-14 years
old
Bolivia

IP* of CD 5-16 years
old
Argentina

Study Design

Prospective
cohort study,

Clinical trial

Clinical trial

Dosing Regimen

BZN: 5–8 mg/kg/day
(mean 6.4
mg/kg/day)
bid (n= 76) or tid (n =
31)
Mean length 60 days

BZN: 5 mg/kg per
day for 60 days

BZN: 5 mg/kg per
day for 60 days NF:
10 mg/kg per day of
for 60 days
(drug source not
stated)

Patients

Therapeutic Effect

Safety

107 enrolled
91 completed

After 3 year follow-up, PCR turned
negative on 99% of patients.
Out of 66 patients with initial
positive F2/3-ELISA that
completed: 72.7% became
negative. (33.3% at end of
treatment, 13.3% at 6 months,
11.1% at 9 months, 8.9% at 26
months, 20% at 36 months and
13.4% at 42 months)

Benznidazole was well tolerated
and ADRs were mild, not
requiring treatment suspension

55 total (20
enrolled/35
completed)

Total 52
BZN: 45
NF: 7

Infected children had higher fecal Firmicutes (Streptococcus,
Roseburia, Butyrivibrio, and Blautia), and lower Bacteroides and also
showed some skin -but not oral- microbiota differences. Treatment
eliminated the fecal microbiota differences from control children,
increasing Dialister (class Clostridia) and members of the
Enterobacteriaceae, and decreasing Prevotella and Coprococcus, with
minor effects on the oral and skin bacterial diversity

Treatment with BZN or NF
induced a decline in T. cruzispecific IFN-g- and IL-2
Posttreatment changes in
several of these markers
distinguished children with a
declining serologic response
suggestive of successful
treatment from those with
sustained serological responses
in a 5-year follow-up study.

Mild ADRs were observed in 8 out
of 40 (20%) subjects under
treatment with BZN, while 5
subjects (12.5%) showed severe
ADRs that resulted in treatment
suspension.
Cutaneous rash and dermatitis
were the main ADRs with BZN
treatment, whereas NF was well
tolerated.
The five children who received
incomplete BZN
dosing were then treated with NF
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Altcheh et al.
2014
8

Rumi et al.
2013
154

Chippaux et
al. 2013
155

IP* of CD* 2-12
years of age (mean
7.3 years)
Argentina
55% Male

IP* of CD* <16 years
of age (range 3-15
years) Argentina

Newborn children
with cCD
Bolivia

Prospective
population
pharmacokinetic
(PK) cohort

BZN: 5-8 mg/kg/day
b.i.d. for 60 days
(mean dose = 6.4)
(Radanil®)

Clinical Trial

BZN: 5 mg/kg/day
b.i.d. for 60 days
(drug source not
stated, assumed
Roche product).

Randomized,
placebounblinded
controlled trial

BZN: 5 mg/kg/day
b.i.d. for 60 days
versus 7.5
mg/kg/day once
daily for 30 days
(Radanil®)
Tablets ground up
and 8, 10, 13, and 15
mg of powder filled
into capsules.

38 enrolled
37 completed

All patients had negative T. cruzi
PCR at Day 60 and at 1.5 year
follow-up with decreased
(compared to pre- treatment) T.
cruzi antibody titers.

At 2-year follow-up (subset at 5year follow-up) almost no
patient demonstrated ELISA
57 treated
seroconversion (however,
45 followed-up
approximately half with reduced
titers) and almost all patients
was PCR negative.

63 BZN 5
mg/kg/day 60
days
61: BZN 7.5
mg/kg/day 30
days

Microhematocrit method used
for diagnosis (all positive pretreatment) for 1 and 2 month
post-treatment follow-up (all
negative).
ELISA serology used at age 8-9
months follow-up (all but 1
patient negative).

Four (10%) patients had ADRs: 1
mild rash, 1 moderate prurigo, 1
generalized rash without systemic
involvement, and 1 moderate
eosinophilia. All ADRs subsided
with symptomatic treatment and
temporary drug discontinuation,
and all patients recovered
neventfully.
Safety reported from 1 of 2 sites
with 32 patients. ADRs in 30% of
patients. Dermatological,
gastrointestinal and neurological
most frequent.
5 mg/kg/day: 38% of patients with
ADRs. Primarily gastrointestinal
and dermatological (5%-10%
frequency).
7.5 mg/kg/day: 31% of patients
with ADRs. Primarily
gastrointestinal and
dermatological (5%-11%
frequency)
Tolerability similar for both
treatment groups. Treatment
temporarily stopped for most
ADRs (<3 days) in both treatment
groups.
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Altcheh et al.
2011
34

IP* of CD 10 days to
19 years of age
(median 6.9 years)
Argentina

Prospective
cohort

BZN: 5-8 mg/kg/day
b.i.d. or t.i.d. for 60
days (mean dose =
6.4) (Radanil®)
Infant doses
provided as
fractioned tablets
administered in milk

107 enrolled
91 completed

257 total
Group A: 59
Group B: 52

Chippaux et
al. 2010
42

Newborn children
with congenital CD
*** Bolivia

Clinical trial

BZN: 2.5 mg/kg/day
b.i.d. for 60 days
Two matched
(Group A) versus 7.5
controls for
mg/kg/day once
each patient
daily for 30 days
enrolled (1 CD
(Group B) (Radanil®)
negative
tablets ground up
mother,
and 8,10, 13 and 15
negative
mg of powder filled
newborn and 1
into capsules
CD positive
mother,
negative
newborn)

Treatment response was high
and persistent, with over 90% of
children who completed 60 days
of treatment presenting a steady
decrease or disappearance of
specific T. cruzi antibodies and a
negative parasitological test (T.
cruzi–specific PCR and
microhematocrit).

Microhematocrit method used
for diagnosis with parallel ELISA
for following course of maternal
versus newborn T. cruzi
antibody titers. No significant
difference between BZN
treatment groups in time course
or degree of reduction in ELISA
titers.

No serious ADRs. 80.6% mild, 16%
moderate, 3.2% severe
(generalized rash). 7 patients
(mostly older) discontinued due to
ADRs. 41% had ADRs related to
treatment:
Dermatological = 21%
CNS = 9 %
Gastrointestinal = 9%
Neuromuscular = 3%
Clinical = 71%
Laboratory changes = 29%
No difference in safety profile by
dosing regimen or gender, but
greater frequency in older
patients.

No safety results reported.

Approximately 90% of treated
newborns had negative ELISA
serology by month 10.
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Escriba et al.
2009
156

Yun et al.
2009
83

Chavez et al.
2006
157

IP* of CD <13 years
(28%<5 years)
Honduras
45% male

IP of CD <18 years of
age.
Honduras = <12
years
Guatemala = <15
years
Bolivia (rural) = <15
years
Bolivia (peri-urban)
=<18 years

IP* of CD 5-10 years
Bolivia

Clinical trial

Clinical trial

Clinical field
(non-controlled)
trial

BZN: 7.5 mg/kg/day
b.i.d. for 60 days
(Radanil®)

BZN: 5-7.5
mg/kg/day b.i.d. or
t.i.d. for 60 days
(source of drug
product not stated
but given Roche
product was only
BZN available at the
time, this is
assumed).

BZN: 8 mg/kg/day
for 60 days (drug
source not states,
assumed Roche
product)

231 enrolled
229 completed
18 month
follow-up

Serology decrease of 75% or
more compared to baseline at
18-month follow up: 88.2% (13
of 27)

48.1% that remained
27 followed for
seropositive at 18-month followan additional
up were seronegative at 361.5 years.
month follow-up.

Total = 2,804
Honduras =
231
Guatemala =
124
Bolivia (rural) =
1,409
Bolivia (periurban)
= 1,040

35

No serious ADRs. Most ADRs mild
or moderate. 3 patients
temporarily discontinued
treatment due to severe adverse
event (neurological).
Gastrointestinal = 27%
Dermatological = 13%
Neurological = 10%
No difference in safety profile by
dosing regimen or gender, but
greater frequency in older
patients.

Serology seroconversion to a
negative result at 18 months
post-treatment:
Honduras = 87.1 %
Guatemala = 58.1%
Bolivia (rural) = 5.4 %
Bolivia (peri-urban) = 0 %

Honduras:
ADRs = 50% of patients; 97% mild,
0% moderate, 3% severe (latter all
neuromuscular-related).
Gastrointestinal = 27%
Dermatological = 13%
Neurological = 10%
Guatemala:
ADRs = 51% of patients; 81% mild,
14%
moderate, 5% severe.
Dermatological = 26%
Gastrointestinal = 25%
Neuromuscular = 23%
Other = 26%

At 14-month follow-up 96%
were still sero-positive on ELISA
(75% of patients showed a
decreased antibody titer of>50%
at 12-month follow-up) and 68%
were positive on PCR

No safety results reported.
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Streiger et al
2004
33

IP* of CD 1-14 years
Argentina

Controlled trial

BZN: 5 mg/kg/day
for 30 days b.i.d

Total: 95

NF: 12–15
mg/kg/day 45–60
days b.i.d or t.i.d

BZN: 64
NF: 7
No-treatment:
24

(Source of drug
product not staten)

IP* of CD <17 years
divided by age of
initiation of therapy:
Schijman et
al. 2003

●

41

●

Galvao et al
2003
35,158

0-6 months of
age
7 months-17
years of age
Argentina

Clinical trial

IP* of CD (range 712 years)
Clinical trial
Brazil (rural)

NF (Lampit®) 10–15
mg/kg/day or BZN:
(Radanil®)
5-8
mg/kg/day b.i.d. for
60 days

BZN: 5-7 mg/kg/day
b.i.d. for 60 days
versus placebo

152 enrolled
40 treated
10 < 3 months
of age
6 from 7
months-2
years of age
24 >3 years of
age

127 (64 BZN /
65 placebo)

Serology seroconversion to a
negative result at any point of
follow up:
NF: 6/7 (85,7%)
BZN: 23/37 (62,2%)
Untreated children did not
change the serology

NF: anorexia, weight-loss, hepatic
enlargement slighty painfully, mild
hepatic and renal toxicitiy (clinical
or laboratory findings)

BZN: vomiting, mild rash. 2
75% of treated children became
patients (3.8%) did not tolerate
negative when treated at ≤4
BZN.
years old and 43% when treated
at ≥9 years old.

Percentage of patients at 2-3year follow-up with
seroconversion (positive to
negative):

No safety results reported.

<3 months of age = 100%
7 months-2 years of age = 67%
>3 years of age = 13%

PCR was applied to a cohort of T.
cruzi-seropositive children who
had been exposed to BZN
chemotherapy or placebo 3
years earlier
PCR at baseline: 84.2% positivity
Untreated patients had a 1.6fold-higher chance of remaining
PCR positive (34 of 53 versus 23
of 58) than those who had
received BZN

No safety results reported.
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Schenone F.
et al 2003
159

Solari et al.
2001
160

Solari et al
1998
161

IP* of CD
0-10 years of age
Chile

Clinical trial

NF (Lampit®): 10
mg/kg/day for 30
days

99

100% negative xenodiagnose,
100% negative PCR after 3 year
follow-up

95,3% well tolerated. 4,7% mild
nauseas. None interrupted.

IP* of CD* 0-10
years
Chile

Clinical trial

NF: Not shown

66

34/36 positive serology at 36
months follow-up, 100%
negative xernodiagnose and PCR

No safety results reported.

IP* of CD
0-10 years
Chile

Clinical trial

NF: 7 mg/kg/day 60
days

28

100% negative xenodiagnose,
35.8% negative PCR

No safety results reported.

Seroconversion to a negative
result after 48 months with
conventional serology:
BZN:11.3% (5 of 44)
Placebo: 4.5% (2 of 44)
Sosa-Estani et
al 1998
40

De Andrade
et al 1996
35

De Andrade
et al 2004
113

IP* of CD (range 612 years)
Argentina

IP* of CD (range 712 years at
enrollement and 1419 years at end of
follow-up)
Brazil (rural)

Randomized,
double-blind,
placebocontrolled trial

Randomized,
double-blind,
placebocontrolled trial

BZN: 5 mg/kg/day
for 60 days
(Radanil®)

BZN: 5-7 mg/kg/day
b.i.d. for 60 days
versus placebo

Total: 106
55 BZN / 51
placebo

130 enrolled
64 BZN/65
placebo

Seroconversion to a negative
result with F29 EIA increased
from 35.7% to 62.1% six and 48
months, respectively, after
treatment.
No placebo-treated child
seroconverted to a negative
result by the end of follow-up
Seroconversion to a negative
result
After 3 years follow up:
BZN: 58% (37 of 64)
Placebo: 5% (3 of 65)
Efficacy of BZN by intention to
treat:55.8%
After 6 years follow up:
BZN: 88.7% (47 of 53),
Placebo: 26.1% (12 of 46)
Efficacy of BZN by intention to
treat: 64.7%

Less than 20% of participants
reported ADRs that included
intestinal colic, cutaneous
maculopapular rush, headache,
anorexia, vomiting, nausea,
diarrhea, dizziness, paresthesia,
and light shivering of the hands.
During treatment only intestinal
colic and rush were more frequent
in the BZN group than in the
placebo group, appearing at days
11.3 and 19.5, respectively. No
severe ADRs were reported. Six
(10%) of 55 in the BZN group had
moderate ADRs.

Minor ADRs requiring no specific
medication were recorded in a
small proportion of individuals
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Table 2: Candidate Chagas disease surrogate biomarkers. Modified from the book Chagas disease, a clinical approach, Freilij, H., Altcheh, J.,
(Chapter Chagas Disease Treatment Efficacy Biomarkers: Myths and Realities, Ruiz-Lancheros et al.)

Biomarker type

Parasite proteins

Parasite recombinant
proteins

Biomarker

Results in Chagas disease

References

Trypomastigotes F2/3 antigenic fraction

Anti F2/3 decreases after BZN treatment and disappears
after 4–21 months in children

120

Immunofluorescence assay of fixed
trypomastigotes (ISIFA)

High titers in infected patients and low titers 6 years
after treatment when patients were considered cured.
High sensitivity and no cross-reactivity with other
diseases

112,162

Trypomastigote mucin antigen A&T CLELISA

Measure anti-Gal Abs. Titers decrease after BZN
treatment in adults and children

113,163,164

Ag13 85 kDa protein with repeats of 5
amino acids

Anti-Ag13 is suitable for CD diagnosis in different
populations, and titers decrease and disappear after 3
years posttreatment

165

T. cruzi ribosomal acid protein P2β

Levels of Anti-P2β decrease in asymptomatic treated CD
patients

166

Immunodominant antigens KMP11,
HSP70, PFR2, Tgp63

A significant drop in reactivity against antigens between
6 and 9 months in BZN treated CD adults at different
stages of the disease. Titers continue to drop after 24
months

167,168

24 kDa calcium-binding protein (rTc24)

Anti-rTC24 Abs decreases within 6–36 months posttreatment

169,170

Flagellar calcium-binding protein (F29)

Sero-reversion for the F29 antigen occurs between 6 and
48 months after BZN treatment in children

40,119

Multiplex 16 r T. cruzi proteins

Decreased response of the panel 36 months after BZN
treatment in adults

118,171

Recombinant complement regulatory
protein (rCRP)

Detect Abs complement-dependent as the CoML test.
Positive reactions decrease 1–2 years after BZN
treatment

172
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Host biochemical
markers

Host prothrombotic
markers

Inmunological
markers

Putative microtubule-associated protein
(MAP) antigen3

Selected antigen from a multiplex array of 15 antigens
Results correlate with PCR-positive and PCR-negative
results in a cohort study 5 years after BZN treatment

ApoA1

Downregulated in CD and normal levels after BZN or NFX
treatment

ApoA1 and FBN fragments

Upregulated in CD and downregulated after BZN or NFX
treatments

174,175

Lytic antibody complement-mediated
lysis (CoML) test

Abs decreases until becoming negative after parasite
elimination in BZN and BFX treatments

170

Prothrombin fragment 1 + 2 (F1 + 2)

A marker of thrombin generation in vivo increases early
in CD and decreases after BZN treatment

176,177

Endogenous thrombin potential (ETP)

Quantifies the ability to generate thrombin when
activated through tissue factor addition upregulated in
CD, decreases after BZN treatment

176,177

Soluble platelet selectin
(sP-selectin)

Biomarker of in vivo platelet activation decrease during
BZN therapy in adults and children

177,178

IFN-γ T cells

Three-fold decrease compared with pretreatment
between 1 and 3 years posttreatment

12

CD3+ T cells

CD3+ T-cell proportion differs between treated and
untreated patients and normalizes in cured patients

179

IL12+ CD14+ cells

BZN-treated children show low levels of IL12+ CD14+
cells and high levels of IL-10 modulated type 1 cytokines
profile

180

CD4+ LIR+ T cells

Decrease of CD4+ LIR+ T cells after treatment between 2
and 6 months and for at least 2 years

47,181

173

174,175
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